These data demonstrate that elevation of A20 in early clinical stages of glioma correlates with poor survival, but differences in A20 expression in the bulk tumor at the time of glioblastoma diagnosis cannot predict survival. This evidence concerns the gene TNFAIP3 and central nervous system cancer.